Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Other Current Liabilities history
Currency unavailable · from the balance sheet
No Other Current Liabilities data reported for this period type.
Other Current Liabilities vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $81.65M USD | +30.8% | +36.9% | 18.8% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $24.77M USD | +294.3% | +42.0% | 16.1% |
| Mar 2026 | $11.15M USD | +65.0% | +89.8% | 2.7% | |
| Mar 2026 | $6.25M USD | +29.9% | +9.3% | 2.3% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $3.08M USD | +46.6% | — | 0.6% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $1.97M USD | — | +136.0% | 0.5% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $1.29M USD | +8.3% | +6.7% | 0.5% |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | +38.7% | +39.5% | 2.3% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.